Pancreatic cancer
A021602
RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)
Trial overview
Topic
A021602
Disease
Pancreas
Description
Primary Objective: To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after prior therapy.
Contact
Physicians
